Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to shrink rectal tumors before surgery

NCT ID NCT07347951

Recruiting now Disease control Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jan 18, 2026 · Last updated May 25, 2026 · Updated 23 times

Summary

This study tests a new treatment plan for people with a certain type of locally advanced rectal cancer (MSS-type). The plan combines short-course radiation, chemotherapy, an immunotherapy drug (serplulimab), and a targeted therapy (bevacizumab) before surgery. The goal is to see if this approach can completely eliminate the cancer before surgery, potentially allowing more patients to avoid a permanent colostomy. The study will enroll 30 adults aged 18-75.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED RECTAL CANCER (LARC)